EBMT 2023 | Validation & differences between the EBMT, CIBMTR, and GIMEMA early myeloma relapse scores
Meral Beksac, MD, Ankara University, Ankara, Turkey, comments on the EBMT, CIBMTR, and GIMEMA early relapse scores for multiple myeloma, explaining that these scores have been validated for the first time in an independent population and will be compared in an upcoming session at EBMT 2023. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Takeda: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Oncopeptides: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
